Biden Could Dismiss FDA Committee’s Pfizer Decision: At Great Cost However

The Food and Drug Administration (FDA) recommended that biotech Pfizer’s COVID-19 booster doses shouldn’t be provided to the general public yet. However, booster doses for people who are 65 years or older or those who fall under high-risk classifications should get a booster dose. This could boost efforts to send vaccine doses to the global south.

The FDA advisory committee overwhelmingly denied a proposal for booster shots of the Pfizer/BioNTech COVID-19 vaccine, which impacts President Joe Biden’s outspoken plans to vaccinate the entire US population with a booster dose once the initial full dosing is complete. The advisory committee voted 16 to 2 against booster vaccines for Americans aged 16 years and older before they unanimously endorsed a plan to give boosters to the high-risk groups that we already mentioned. The committee, known as the FDA Vaccines and Related Biological Products Advisory Committee, has reached a non-binding conclusion that the Pfizer application was a step too far at this current time.

But that is a part of the issue. The FDA’s vaccine advisory committee can issue as many recommendations as they want, but they aren’t binding by law nor federal regu...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee